Guía de Práctica Clínica sobre Lupus Eritematoso Sistémico

568 Zhu D, Qu Z, Tan Y, Yu F, Zhao M-H. Acute kidney injury in Chinese patients with
lupus nephritis: a large cohort study from a single center. Lupus 2011; 20: 1557–1565.
569 Ponte B, Felipe C, Muriel A, Tenorio MT, Liaño F. Long-term functional evolution after
an acute kidney injury: a 10-year study. Nephrol Dial Transplant 2008; 23: 3859–3866.
570 Chen T, Ding X, Chen B. Value of the RIFLE classification for acute kidney injury in
diffuse proliferative lupus nephritis. Nephrol Dial Transplant 2009; 24: 3115–3120.
571 Yu F, Tan Y, Liu G, Wang S, Zou W, Zhao M. Clinicopathological characteristics and
outcomes of patients with crescentic lupus nephritis. Kidney Int 2009; 76: 307–317.
572 Chin HJ, Ahn C, Lim CS, Chung HK, Lee JG, Song YW et al. Clinical implications of
antineutrophil cytoplasmic antibody test in lupus nephritis. Am J Nephrol 2000; 20: 57–63.
573 Hu WX, Liu ZZ, Chen HP, Zhang HT, Li LS, Liu ZH. Clinical characteristics and
prognosis of diffuse proliferative lupus nephritis with thrombotic microangiopathy. Lupus
2010; 19: 1591–8.
574 Yu F, Wu L-H, Tan Y, Li L-H, Wang C-L, Wang W-K et al. Tubulointerstitial lesions of
patients with lupus nephritis classified by the 2003 International Society of Nephrology
and Renal Pathology Society system. Kidney Int 2010; 77: 820–9.
575 Walsh M, Solomons N, Lisk L, Jayne DRW. Mycophenolate mofetil or intravenous
cyclophosphamide for lupus nephritis with poor kidney function: a subgroup analysis of
the Aspreva Lupus Management Study. Am J Kidney Dis 2013; 61: 710–715.
576 Rivera F, Illescas ML, López-Rubio E, Fulladosa J, Poveda R, Baltar J et al.
Mycophenolate as maintenance therapy for lupus nephritis with impaired renal function.
Am J Nephrol 2013; 37: 509–517.
577 Kong KO, Badsha H, Lian TY, Edwards CJ, Chng HH. Low-dose pulse
methylprednisolone is an effective therapy for severe SLE flares. Letter to the Editor.
Lupus 2004; 13: 212–213.
578 Haubitz M, Bohnenstengel F, Brunkhorst R, Schwab M, Hofmann U, Busse D.
Cyclophosphamide pharmacokinetics and dose requirements in patients with renal
insufficiency. Kidney Int 2002; 61: 1495–1501.
579 Houssiau FA, D’Cruz D, Sangle S, Remy P, Vasconcelos C, Petrovic R et al. Azathioprine
versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results
from the MAINTAIN Nephritis Trial. Ann Rheum Dis 2010; 69: 2083–2089.
580 Stoenoiu MS, Aydin S, Tektonidou M, Ravelingien I, le Guern V, Fiehn C et al. Repeat
kidney biopsies fail to detect differences between azathioprine and mycophenolate mofetil
maintenance therapy for lupus nephritis: data from the MAINTAIN Nephritis Trial.
Nephrol Dial Transplant 2012; 27: 1924–1930.
581 Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D et al. Mycophenolate
versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011; 365:
1886–1895.
478 GUÍAS DE PRÁCTICA CLÍNICA EN EL SNS